
    
      This is an open-label safety and tolerability study in which approximately 600 subjects will
      receive NKTR-181 for up to 52 weeks. Subjects may include newly enrolled subjects and
      subjects who have recently completed SUMMIT-07 study.

      This study will also investigate the pharmacokinetics of NKTR-181 in patients with chronic
      low back pain or chronic non-cancer pain.
    
  